A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases

In the context of amelanotic melanoma, little is known on the genetic or molecular background that determines the onset of this peculiar phenotype of melanoma and its sites of metastatic spread. However, it appears that amelanotic melanomas frequently lack BRAF mutations.

[1]  Lauren E Haydu,et al.  Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.

[2]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[3]  T. Saida,et al.  Molecular Diagnostics , 2013, BioMed research international.

[4]  A. Hirshberg,et al.  Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. , 2008, Oral oncology.

[5]  S. Piana,et al.  Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. , 2013, The Journal of clinical endocrinology and metabolism.

[6]  R. Friedrich,et al.  Distant metastases and malignant cellular neoplasms encountered in the oral and maxillofacial region: analysis of 92 patients treated at a single institution. , 2010, Anticancer research.

[7]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Millikan,et al.  Tandem BRAF mutations in primary invasive melanomas. , 2004, The Journal of investigative dermatology.

[9]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[10]  M. Mazumdar,et al.  Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma , 2012, PloS one.

[11]  S. Meehan,et al.  Amelanotic melanoma: a detailed morphologic analysis with clinicopathologic correlation of 75 cases , 2012, Journal of cutaneous pathology.

[12]  M. Trivett,et al.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.

[13]  K. Aldape,et al.  Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. , 2013, The Journal of molecular diagnostics : JMD.

[14]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[15]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[16]  L. Heinzerling,et al.  Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice , 2013, British Journal of Cancer.